Get started
Author

Yoshimi Aoyagi

Observed names: Y Aoyagi, Y. Aoyagi, YOSHIMI AOYAGI
OpenAlex ID: A5067486875
Antitumor Activity of a Novel Quinoline Derivative, TAS‐103, with Inhibitory Effects on Topoisomerases I and II
1997 · Teruhiro Utsugi, Kumio Aoyagi, et al. · Japanese Journal of Cancer Research · 118
TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations
2018 · Shinichi Hasako, Miki Terasaka, et al. · Molecular Cancer Therapeutics · 88
Synthesis of the novel analogues of dysidiolide and their structure–activity relationship
2000 · Masato Takahashi, Kosuke Dodo, et al. · Bioorganic & Medicinal Chemistry Letters · 63
In vitro Antitumor Activity of TAS‐103, a Novel Quinoline Derivative That Targets Topoisomerases I and II
1999 · Yoshimi Aoyagi, Takashi Kobunai, et al. · Japanese Journal of Cancer Research · 41
PDF
New Cdc25B Tyrrosine Phosphatase Inhibitors, Nocardiones A and B, Produced by Nocardia sp. TP-A0248. Taxonomy, Fermentation, Isolation, Structural Elucidation and Biological Prbperties.
2000 · TOSHIO OTANI, YOSHIKAZU SUGIMOTO, et al. · The Journal of Antibiotics · 40
PDF
The Novel VEGF Receptor/MET–Targeted Kinase Inhibitor TAS-115 Has Marked In Vivo Antitumor Properties and a Favorable Tolerability Profile
2013 · Hidenori Fujita, Kazutaka Miyadera, et al. · Molecular Cancer Therapeutics · 38
TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect.
2005 · Yasuji Yamamoto, Jiro Shibata, et al. · PubMed · 34
TAS-108, a Novel Oral Steroidal Antiestrogenic Agent, Is a Pure Antagonist on Estrogen Receptor α and a Partial Agonist on Estrogen Receptor β with Low Uterotrophic Effect
2005 · Yasuji Yamamoto, Jiro Shibata, et al. · Clinical Cancer Research · 32
PDF
A novel cinnamic acid derivative that inhibits Cdc25 dual‐specificity phosphatase activity
2005 · Yoshimi Aoyagi, Norio Masuko, et al. · Cancer Science · 24
PDF
TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719X
2019 · Kimihiro Ito, Makoto Nishio, et al. · Molecular Cancer Therapeutics · 12
Anticancer effect of 4-[3,5-bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) against A549 non-small cell lung cancer cell line is related to its anti-invasive activity.
2000 · J Shibata, K Murakami, et al. · PubMed · 8
Establishment and Characterization of 6‐[[2‐(Dimethylamino)ethyl]amino]‐3‐hydroxy‐7H‐indeno[2,1‐c]quinolin‐7‐one dihydrochloride (TAS‐103)‐resistant Cell Lines
2000 · Yoshimi Aoyagi, Takashi Kobunai, et al. · Japanese Journal of Cancer Research · 7
PDF
142 TAS-2913 is a Mutant Selective EGFR Inhibitor for NSCLC: Characterization Against EGFR T790M in Cell and Xenograft Models
2012 · K. Miyadera, M. Kato, et al. · European Journal of Cancer · 3
401 TAS-121, a highly potent and mutant-specific EGFR inhibitor, overcomes T790M-acquired resistance with promising antitumor activity through specific inhibition of mutant EGFR signaling
2014 · M. Kato, K. Miyadera, et al. · European Journal of Cancer · 2
Abstract C111: In vitro characterization of TAS-121, a novel, highly potent, and mutant-specific EGFR-TKI.
2013 · Kimihiro Ito, Kazutaka Miyadera, et al. · Molecular Cancer Therapeutics · 2
Abstract 3577: TAS-115: a highly potent c-Met + VEGFRs dual inhibitor with prominently safer profile
2011 · Hidenori Fujita, Kazutaka Miyadera, et al. · Cancer Research · 2
Abstract 3600: The prominent safety profile of TAS-115, a novel c-Met + VEGFR dual kinase inhibitor can lead to potentiate the efficacy via durable inhibition of angiogenesis
2011 · Hiroaki Ochiiwa, Hidenori Fujita, et al. · Cancer Research · 2
MO13-2 Covalent FGFR inhibitor futibatinib exhibits sustained antitumor effects compared with ATP-competitive inhibitors
2023 · Hiromi Muraoka, Hiroshi Sootome, et al. · Annals of Oncology · 1
Abstract C112: Characterization of TAS-121, a novel mutant-specific EGFR-TKI, on pharmacokinetics, pharmacodynamics, and antitumor activity.
2013 · Masanori Kato, Kazutaka Miyadera, et al. · Molecular Cancer Therapeutics · 1
Abstract 1785: MET/VEGFR dual inhibition and prominent safety profile of TAS-115 are favorable for the combination with chemotherapeutic drugs
2012 · Hidenori Fujita, Masanori Kato, et al. · Cancer Research · 1
Abstract 5863: Enhanced antitumor activity of zipalertinib and amivantamab combination in EGFR mutant NSCLC models
2026 · Kohei Hayashi, Yoshimi Aoyagi, et al. · Cancer Research
37eP Translational preclinical evaluation of zipalertinib in an amivantamab-resistant EGFR exon 20 insertion NSCLC model
2025 · K. Hayashi, K. Hamamoto, et al. · Annals of Oncology
Data from The Novel VEGF Receptor/MET–Targeted Kinase Inhibitor TAS-115 Has Marked In Vivo Antitumor Properties and a Favorable Tolerability Profile
2023 · Hidenori Fujita, Kazutaka Miyadera, et al.
Data from The Novel VEGF Receptor/MET–Targeted Kinase Inhibitor TAS-115 Has Marked In Vivo Antitumor Properties and a Favorable Tolerability Profile
2023 · Hidenori Fujita, Kazutaka Miyadera, et al.
Supplementary Figures 1 through 5 and Supplementary Tables 1 through 3 from The Novel VEGF Receptor/MET–Targeted Kinase Inhibitor TAS-115 Has Marked In Vivo Antitumor Properties and a Favorable Tolerability Profile
2023 · Hidenori Fujita, Kazutaka Miyadera, et al.
PDF
Works count: 63
Citation count: 519
H-index: 10
I10-index: 10
Year
Topic
Type